The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum.

Ann Oncol · 2011 · PMC3042921 · PMID 20616198

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

While the MA.17 and the ABCSG-6a study reported significantly improved DFS and recurrence-free survival, respectively, by adding the aromatase inhibitor after 5 years on tamoxifen, a nonsignificant trend was observed in the NSABP B-33 study.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.